{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T02:45:13Z","timestamp":1786243513540,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","award":["22JCYBJC00700"],"award-info":[{"award-number":["22JCYBJC00700"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571535"],"award-info":[{"award-number":["82571535"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171338"],"award-info":[{"award-number":["82171338"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clineuro.2026.109465","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:21:49Z","timestamp":1778577709000},"page":"109465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efgartigimod in myasthenia gravis: Efficacy and steroid-sparing benefits in a real-world cohort"],"prefix":"10.1016","volume":"268","author":[{"given":"Xiao-Na","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-Yu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0846-2851","authenticated-orcid":false,"given":"Chun-Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2026.109465_bib1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"ADAPT Investigator Study Group, Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2026.109465_bib2","article-title":"ADAPT+ Study Group, Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clineuro.2026.109465_bib3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2026.109465_bib4","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2026.109465_bib5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in myasthenia gravis clinical research and care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clineuro.2026.109465_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2026.109465_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.clineuro.2026.109465_bib8","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","article-title":"Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)","volume":"270","author":"Sacc\u00e0","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2026.109465_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/WCO.0000000000001088","article-title":"Novel pathophysiological insights in autoimmune myasthenia gravis","volume":"35","author":"Masi","year":"2022","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.clineuro.2026.109465_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jnnp-2019-322640","article-title":"Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs","volume":"91","author":"Cetin","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2026.109465_bib11","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s40265-023-01933-1","article-title":"Rozanolixizumab: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.clineuro.2026.109465_bib12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Mg0003 Study Team, Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2026.109465_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114603","article-title":"Efficacy of multi-cycle Efgartigimod in achieving minimal symptom expression in myasthenia gravis: a comparative multi-center study","volume":"154","author":"Chen","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clineuro.2026.109465_bib14","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40120-025-00748-4","article-title":"Real-world experience with FcRn inhibitors efgartigimod and rozanolixizumab in myasthenia gravis: administration in multiple cycles and transition from intravenous to subcutaneous formulation","volume":"14","author":"Yoshikawa","year":"2025","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.clineuro.2026.109465_bib15","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2147\/JIR.S455104","article-title":"Therapeutic plasma exchange in AChR-Ab positive generalized myasthenia gravis: a real world study about its early response","volume":"17","author":"Chen","year":"2024","journal-title":"J. Inflamm. Res."},{"issue":"6","key":"10.1016\/j.clineuro.2026.109465_bib16","article-title":"Immunomodulators and immunosuppressants for myasthenia gravis: a network meta-analysis","author":"Varela","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.clineuro.2026.109465_bib17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3803\/EnM.2020.659","article-title":"Effects of systemic glucocorticoid use on fracture risk: a population-based study","volume":"35","author":"Koh","year":"2020","journal-title":"Endocrinol. Metab. (Seoul.)"},{"key":"10.1016\/j.clineuro.2026.109465_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16189","article-title":"Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center","volume":"31","author":"Frangiamore","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clineuro.2026.109465_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241311127","article-title":"Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study","volume":"18","author":"Zhu","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2026.109465_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mus.28003","article-title":"Single institution experience with efgartigimod in patients with myasthenia gravis: patient selection, dosing schedules, treatment response, and adverse events","volume":"69","author":"Singer","year":"2024","journal-title":"Muscle Nerve"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846726001575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846726001575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T02:25:00Z","timestamp":1786242300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846726001575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":20,"alternative-id":["S0303846726001575"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2026.109465","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efgartigimod in myasthenia gravis: Efficacy and steroid-sparing benefits in a real-world cohort","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2026.109465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109465"}}